Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin
- 3 March 2016
- journal article
- research article
- Published by Maney Publishing in Journal of Chemotherapy
- Vol. 28 (2) , 83-88
Abstract
Objectives: To reassess the activity of telavancin when tested against Gram-positive clinical pathogens recovered from hospitalized patients in European and adjacent regions using a revised broth microdilution method. Methods: 11 601 consecutive, non-duplicate isolates originating from 36 institutions among 18 countries recovered between 2011 and 2013 were tested for susceptibility using a revised broth microdilution method for telavancin. Interpretive telavancin breakpoints appropriate for the method were those recently approved by the FDA and EUCAST, as available. Results: Telavancin (MIC50/90, 0.03/0.06 mg/l; 100.0% susceptible) was equally potent against methicillinsusceptible ((MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus. All Enterococcus faecalis was susceptible to telavancin (MIC50/90, 0.12/0.12 mg/l) and inhibited at the susceptibility breakpoint (i.e. <= 0.25 mg/l), except for VanA-phenotype vancomycin-resistant isolates (telavancin MIC, > 1 mg/l). Telavancin (<= 0.015/0.03 mg/I) was active against vancomycin-susceptible Enterococcus faecium, while higher MIC values were obtained for VanA strains. Telavancin (both MIC50 and MIC90 <0.015 mg/l) was potent against Streptococcus pneumoniae, beta-haemolytic streptococci (MIC50/90, <= 0.015/0.06 mg/l) and viridans group streptococci (MIC50/90, <= 0.015/0.03 mg/l). Conclusions: Telavancin exhibited potent activity against this contemporary (2011-2013) collection of organisms, inhibiting indicated pathogens at or below the FDA/EUCAST-approved breakpoints for susceptibility. VanA-phenotype enterococci were less susceptible to telavancin, a feature observed using the previous testing method. These results redefine telavancin's activity against isolates from Europe.Keywords
This publication has 18 references indexed in Scilit:
- Revised Reference Broth Microdilution Method for Testing Telavancin: Effect on MIC Results and Correlation with Other Testing MethodologiesAntimicrobial Agents and Chemotherapy, 2014
- Quality Control MIC Ranges Used for Telavancin with Application of a Revised CLSI Reference Broth Microdilution MethodJournal of Clinical Microbiology, 2014
- In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumoniaDiagnostic Microbiology and Infectious Disease, 2012
- Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time killDiagnostic Microbiology and Infectious Disease, 2012
- Further Insights into the Mode of Action of the Lipoglycopeptide Telavancin through Global Gene Expression StudiesAntimicrobial Agents and Chemotherapy, 2012
- Evaluation of Telavancin Activity versus Daptomycin and Vancomycin against Daptomycin-Nonsusceptible Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2012
- Update on the telavancin activity tested against European staphylococcal clinical isolates (2009–2010)Diagnostic Microbiology and Infectious Disease, 2011
- Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection StudiesAntimicrobial Agents and Chemotherapy, 2009
- Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United StatesAntimicrobial Agents and Chemotherapy, 2008
- In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance InitiativeJournal of Antimicrobial Chemotherapy, 2008